Navigation Links
Actos Lawyers at Bernstein Liebhard LLP Comment on California Judge’s Decision to Set Aside Verdict in Nation’s First Actos Bladder Cancer Trial
Date:5/3/2013

New York, New York (PRWEB) May 03, 2013

The Actos lawyers at Bernstein Liebhard LLP note that a California Superior Court judge has set aside a $6.5 million verdict handed down last week in the nation’s first Actos bladder cancer trial. According to a May 3rd Reuters report, in granting Takeda Pharmaceuticals' request to nullify the verdict, Judge Kenneth Freeman of Los Angeles Superior Court asserted that the Plaintiff’s medical expert had failed to establish that Actos was the specific cause of Cooper's bladder cancer.* (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

“We are obviously disappointed with this turn of events, but we are still heartened that the first jury to hear an Actos claim found for the plaintiff. We remain optimistic that future Actos bladder cancer lawsuits will yield victories for plaintiffs,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to long-term users of the medication who have been diagnosed with bladder cancer.

Actos Bladder Cancer Lawsuits
Court records indicate that Takeda has been named in more than 3,000 Actos bladder cancer lawsuits. Some 1,200 of those Actos lawsuits have been filed in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. The first trial in that litigation is expected to begin next January. (In re: Actos Product Liability Litigation, MDL No. 2299) All of the Actos lawsuits allege Takeda knew that Actos could increase the risk of bladder cancer in patients taking the drug, but failed to provide adequate warnings about this increased risk.

According to court documents, the Plaintiff in the Los Angeles Actos bladder cancer trial had taken the drug for four years before being diagnosed with the disease. According to an April 15th Bloomberg.com story, evidence introduced at trial included internal Takeda emails that suggested company officials were worried about the impact an Actos bladder cancer warning would have on sales of the drug. The Plaintiff’s attorneys also told the jury that Takeda had known about the connection between Actos and bladder cancer since 2004, but did not inform regulators for 7 years.**

The litigation surrounding Actos has been growing since June 2011, when the U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label, after a study found that long-term use increased the risk for bladder cancer.*** According to a February 28th Bloomberg.com report, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.****

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please call (877) 779-1414 today.

  • newsandinsight.thomsonreuters.com/Legal/News/2013/05_-_May/Judge_sets_aside_$6_5_mln_verdict_in_first_Takeda_Actos_trial/
** bloomberg.com/news/2013-04-15/takeda-s-actos-diabetes-drug-tied-to-cancer-jury-is-told.html
*** fda.gov/drugs/drugsafety/ucm259150.htm
****bloomberg.com/news/2013-02-28/takeda-didn-t-warn-of-actos-cancer-risk-lawyer-says.html

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10700182.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
2. Chaffin Luhana Alerts Actos Patients to Updated MDL Trial Dates
3. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
4. 2013 Actos Bladder Cancer Claims Now Being Investigated by Resource4thePeople Attorneys
5. DrugRisk Center Adds Latest on First of 3,000 Actos Bladder Cancer Trials
6. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
7. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
8. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
9. Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
10. US Drug Watchdog Now Urges All Diabetics Nationwide Who Used the Diabetes Drug Actos and now have Bladder Cancer to Call The Johnson Law Group For A Legal Evaluation
11. US Drug Watchdog Now Urges Diabetics Who Used the Diabetes Drug Actos and Then Developed Bladder Cancer to Call the Johnson Law Group for a Legal Review - Get Compensated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and ... it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, ... American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on ...
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
(Date:4/27/2017)... DC (PRWEB) , ... April 27, 2017 , ... ... Behavioral Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking ... recognition (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: